semaj83/ctmatch_classification huggingface dataset:
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Major Depressive Disorder Not currently participating in a drug or medical device clinical trial Male or female over the age of 18 DSM IV Diagnosis of major depression Positive family history of bipolar disorder or completed suicide  Not able to give informed consent Pregnant or breast-feeding Current additional psychiatric diagnoses including Panic Disorder, Post -Traumatic Stress Disorder (PTSD) or Psychosis History of mania or hypomania Active substance abuse or dependence in the last 6 months Current depressive episode less than 4 weeks or greater than 12 months in duration Current or prior adequate trial of lithium or paroxetine Current use of other medications such as antidepressants for the treatment of depression Clinically significant medical illness, in particular kidney problems
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancer Anorexia Weight Loss Insomnia Advanced cancer patients seen in outpatient clinics or inpatient units at MD Anderson Cancer Center, with presence of anorexia for at least one month, and accompanied by weight loss of > 5 % of pre-illness body weight in the last 6 months. Anorexia on the day of enrollment (day 0 +/-3) must be > 4/10 on ESAS Patients > 18 years of age Karnofsky Performance score of > 40 at time of into study Ability to provide informed consent and comply with study procedures Ability and willingness to return to engage in telephone follow-up by research nurse on days 2 (+/ days), 8 (+/ days), 16 ( +/ days), and 22 (+/ days) and return to outpatient clinic for evaluation on days 15 (+/ days), and 29 (+/  Patients who have known dementia or delirium at time of enrollment as determined by a physician Known hypersensitivity to any ingredient of Mirtazapine Inability to maintain oral intake over the course of the study, such as with mechanical obstruction of the alimentary tract or intractable vomiting Ongoing use of tube feeding or parenteral nutrition Current use of corticosteroids (with the exception of scheduled doses during time of chemotherapy), dronabinol, testosterone and progesterone derivatives such as megestrol acetate, or in the preceding 1 week prior to study enrollment Pregnancy or lactation or unwillingness to use contraceptives A score of 11 or more, in each subscale of the Hospital Anxiety and Depression scale (HADS) indicating clinical depression or anxiety. Those with HADS scores of > 11 at baseline indicating moderate or severe depression will be excluded from the study and will be referred for appropriate follow up by counselor and psychiatry evaluation Patients on chronic use of benzodiazepines are excluded
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Fatigue Gastrointestinal Cancer Patient diagnosed with breast, gastrointestinal, lymphoma, myeloma or lung cancer undergoing chemotherapy or hormonal treatment Patient is > or = 18 years of age Patient has Brief Fatigue Inventory "fatigue worst" score of > or = 4 at baseline Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of < or = 2 at baseline Patient has a life expectancy > or = 6 months from the start of the study Patient is using acceptable birth control methods. Female participants (if of child bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control. Medically acceptable methods of contraception abstinence, birth control pills, diaphragm with spermicide, condom with foam or spermicide, vaginal spermicidal suppository or surgical sterilization Patient must speak and understand English Patient has provided written informed consent to participate in the study prior to enrollment to the study  History of hypersensitivity reaction to methylphenidate History of or current seizure disorder, glaucoma, major psychiatric diagnosis, narcolepsy, Tourette's syndrome, tension or agitation History of clinically significant cardiac disease Uncontrolled hypertension: has not been on a stable treatment dose for the past month, or has a systolic pressure consistently (defined as 3 consecutive blood pressure readings within the last 30 days) greater than 150 mm Hg or diastolic pressure consistently greater than 85 mm Hg History of fibromyalgia Use of alcohol while participating in the study Current use of illicit drugs or history of alcohol or drug abuse and/or abuse potential (see protocol for criteria) Moderate to severe depression (> or = 20 on Beck Depression Index II) If taking antidepressants, no changes in dose and/or no start of new course of treatment in the last 30 days Currently taking psychostimulants (including appetite suppressants), monoamine oxidase (MAO) inhibitors, anticoagulant or anticonvulsant therapy
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Obsessive Compulsive Disorder primary OCD diagnosis according to DSM IV current symptoms were responsible for significant distress previous trial of at least 12 weeks with SSRI (being at least 8 weeks at maximum tolerated dosage) failed to produce full remission of OCD symptoms  presence of clinical or neurological diseases that may be worsen by the medications included in treatment protocol current substance dependence or abuse current psychotic symptoms current suicide risk and current pregnancy or intention to get pregnant before the end of the treatment protocol
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Atypical Depression age 18 to 65 years DSM-IV episode of Major Depression non-psychotic with atypical features ≥19 score on the 29-item HAM-D ability to give informed consent, if patients are of child-bearing potential A minimum 2-week washout from existing psychotropics (5 weeks for fluoxetine)  bipolar depression Any Axis I psychotic disorder currently suicidal or suicide risk history of substance abuse in the previous 12 months history of hypersensitivity to escitalopram, or citalopram serious or unstable medical disorders starting or terminating psychotherapy during the previous 12 weeks ECT treatment in the previous 3 months pregnancy or planning pregnancy
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Postpartum Depression Major Depressive Disorder adult female subjects age 18 and above if onset of depression within 4 weeks of delivery,or onset of depression antenatally either during pregnancy or before pregnancy must score greater than or equal to 12 on the Edinburgh Postnatal Depression Scale speak English or Spanish have access to a telephone provide written and verbal consent  have current or lifetime psychosis an unstable medical condition hypertension narrow-angle glaucoma liver disease seizure disorders bulimia anorexia mania substance abuse disorders
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Depression Anxiety Female Student in grades 6 through 8 Student in participating school  Male
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Major Depressive Disorder All subjects will meet DSM-IV for depression on the basis of a SCID-P interview, with subjects having a score on the 17-item Ham-D > 17 (with item #1 > 2) Subjects will meet both at recruitment and after a one-week single blind placebo wash-in. Study includes outpatients only  All subjects will have no serious medical illness. The investigators will patients also meeting for the following groups of axis I diagnoses delirium or dementia substance-related disorders schizophrenia or other psychotic disorders, or eating disorders In addition, patients meeting for cluster A or B axis II diagnoses will be excluded Subjects with a history of current or past active suicidal ideation, or suicide attempts will be excluded from the study
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Sleep Initiation and Maintenance Disorders Depression Meets for Major Depressive Disorder Between 18 and 75 years of age and adequately fluent in English Meets for an insomnia disorder  Women who are currently pregnant, breast-feeding, or not using a reliable birth control method People for whom the antidepressant medication(s) provided in the study is not indicated People who have had minimum adequate trials of (or have not been able to tolerate) all three study medications People with uncontrolled medical conditions People with moderate or severe sleep disorders other than insomnia Individuals on a fixed night shift or rotating work schedule that requires a night shift Patients with a current principal diagnosis of a psychiatric disorder that necessitates treatment that is not offered in the study
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Schizophrenia Key The patient has a diagnosis of schizophrenia according to the DSM-IV-TR and the patient has been clinically stable in a nonacute phase of their illness Documentation that the patient has received treatment with olanzapine, oral risperidone, or paliperidone for schizophrenia for at least 6 weeks prior to the screening visit and has been on a stable dose of that antipsychotic medication for at least 4 weeks prior to the screening visit The patient is in good health (except for the diagnosis of schizophrenia) as judged by the investigator Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception barrier method with spermicide, intrauterine device (IUD), steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method, or documented abstinence The patient has a PANSS negative symptom score of 15 or more at the screening and baseline visits Key  The patient has a severity rating of moderate or worse on any item of the PANSS positive symptom subscale The patient has any Axis I disorder according to DSM-IV-TR including schizoaffective disorder, apart from schizophrenia and nicotine dependence, or any Axis II disorder that would interfere with the conduct of the study The patient has moderate to severe depressive symptoms, as indicated by the CDSS The patient has current active suicidal ideation, is at imminent risk of self-harm, or has a history of significant suicidal ideation or suicide attempt at any time in the past that causes concern at present The patient has tardive dyskinesia, akathisia, moderate or worse level of extrapyramidal symptoms, or any other clinically significant movement disorder The patient has a history of any cutaneous drug reaction or drug hypersensitivity reaction, a history of any clinically significant hypersensitivity reaction, or has a history of multiple clinically relevant allergies The patient is a pregnant or lactating woman The patient has previously received modafinil or armodafinil, or the patient has a known sensitivity to any ingredients in the study drug tablets
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthritis, Rheumatoid The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria The patient has active disease at both Screening and Baseline, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 at Screening: 1.ESR (Westergren method) >28 mm in the local laboratory. 2. CRP >7 mg/L in the central laboratory Patient had an inadequate response to at least one DMARD (traditional or biologic) due to lack of efficacy or toxicity No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis Patient has washed out of all DMARDs other that antimalarials  Blood dyscrasias including confirmed: 1. Hemoglobin <9 g/dL or Hematocrit <30%; 2. White blood cell count <3.0 x 109/L; 3. Absolute neutrophil count <1.2 x 109/L; 4. Platelet count <100 x 109/L History of any other autoimmune rheumatic disease other than Sjogren's syndrome No malignancy or history of malignancy History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 13.0-18.0,  Major Depressive Disorder for Major Depressive Disorder Participants Participants must meet DSM-IV-TR for Major Depressive Disorder, with current mood state depressed for ≥ 2 weeks Participants must be females Participants must be between the age of 13 and 18 years Participants must have had an adequate trial of fluoxetine, defined as a trial of ≥ 8 weeks of treatment, with a dose of ≥ 40mg daily for ≥ 4 weeks. If the participant had a trial of 40mg daily and was unable to tolerate it, a dose of 20mg for ≥ 8 weeks is acceptable; OR Participants must have had an adequate trial of escitalopram, defined as a trial of ≥ 8 weeks of treatment, with a dose of ≥ 20 mg daily for ≥ 4 weeks. If the participant had a trial of 20 mg daily and was unable to tolerate it, a dose of 10 mg for ≥ 8 weeks is acceptable Participants must have a CDRS-R score of ≥ 40 and a CGI-S score of ≥ 4 Participants must be able to give informed consent or assent, and where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation for Healthy Control Participants Participants must be females  for Treatment-Resistant Major Depressive Disorder Participants Unstable co-morbid medical, neurological or psychiatric disorder Pre-existing renal disease Proteinuria or microalbuminuria Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice birth control during the study. Participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS brain scan High risk for suicidal behavior, homicidal behavior or self-harm Adolescents who are unlikely to be able to comply with the study protocol DSM-IV-TR for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence Contraindication to MRI/MRS brain scans, such as ferromagnetic implants or claustrophobic anxiety Documented or suspected history of intellectual disability (Full-Scale I.Q. < 70)
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 20.0-50.0,  SSRI-Refractory Obsessive-Compulsive Disorder Male or female, 18 years of age or over Patients were diagnosed as having obsessive-compulsive disorder by the Structured Clinical Interview for DSM-IV Patient version (SCID-P) They received standardized treatment for at least 1 year at the OCD clinic in our university hospital Each subject gave written informed consent to take part after receiving a complete description of this study All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period  Current clinically significant medical conditions such as diabetes
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Epilepsy Depression Healthy For Control Group Healthy adults of 18 years of age or older  Subject has no history of affective disorders Subject scores higher than 5 on Hamilton Depression Rating Scale Subject with prior primary diagnosis of any psychotic disorder, bipolar disorder, anxiety disorder, or any other serious medical or neurological disorder Subject is pregnant Subject is unable to undergo a MRI Epilepsy Only Group Subject is at least 18 years of age Subject has confirmed temporal lobe epilepsy (TLE) Subject has a history of depression Subject scores higher then 5 on Hamilton Depression Rating Scale
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Atypical Depression Main Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months Female and male Caucasians aged 18 to 70 years At least one of HAMD-28 scale items 22-26 scores >1